Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin.
about
Localization of prohibitin in the nuclear matrix and alteration of its expression during differentiation of human neuroblastoma SK-N-SH cells induced by retinoic acid.Aberrant expression of nuclear matrix proteins during HMBA-induced differentiation of gastric cancer cellsSuppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF-κB-dependent MMP-9 expression.Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.Safety and tolerability of Panax ginseng root extract: a randomized, placebo-controlled, clinical trial in healthy Korean volunteersTanshinone IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro associated with mitochondrial dysfunction.Proteomics of osteosarcoma.Miltirone exhibits antileukemic activity by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction pathways.Nucleophosmin Regulates Intracellular Oxidative Stress Homeostasis via Antioxidant PRDX6.Isolation of a new bioactive cinnamic acid derivative from the whole plant of Viola betonicifolia.Salvia officinalis L. extract and its new food antioxidant formulations induce apoptosis through mitochondrial/caspase pathway in leukemia L1210 cells.In silico studies for the interaction of tumor necrosis factor-alpha (TNF-α) with different saponins from Vietnamese ginseng (Panax vietnamesis).Evaluation of the adaptogenic potential exerted by ginsenosides Rb1 and Rg1 against oxidative stress-mediated neurotoxicity in an in vitro neuronal model.Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer.Relocation of NPM Affects the Malignant Phenotypes of Hepatoma SMMC-7721 Cells.
P2860
Q33742330-A798C5D1-CAED-4BAB-B3D9-BE9F3B2E03D5Q33830761-03EE465A-E3CB-4FD4-8C8B-B9C922302E84Q34372172-18741B5F-DC5F-4CA3-8826-5B799D42261EQ34973863-01165565-D435-4E30-BA4F-87C7A0C55124Q35787329-3761EBC2-8D0C-41C3-852E-F514C2523159Q36407774-917A9749-952E-4A95-BD0F-42F1C7DD8BC1Q37595420-E84FD8A0-66D2-4C61-95A2-DA1F29F05566Q38198116-CA8DF43F-3170-4DC5-A106-CD5095A061E9Q38265967-255CD9FE-2088-4EDF-B775-437FCFEE778DQ38780814-772236C3-60E6-4382-9E0E-A4411BB10E14Q39313251-BFDA87AC-9653-44ED-8B4D-A765E372C537Q40742552-799749E5-C9DB-4D14-837B-7B1B4FF6B9E0Q41227150-5B01CAAC-3698-40D6-9311-3AA9EBE094D9Q41432901-2BCE9123-C72B-4A11-BC3B-269209C44B43Q48085820-4C2F2BA9-F6BE-4549-A5EE-0456DA23DEA3Q48161681-3E64B330-6F6F-4984-A217-9117DDCAE01B
P2860
Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@ast
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@en
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@nl
type
label
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@ast
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@en
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@nl
prefLabel
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@ast
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@en
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@nl
P2093
P1476
Anticancer effects of ginsenos ...... trafficking of nucleophosmin.
@en
P2093
Jianye Song
Song-Lin Shi
Ying Liang
P304
P356
10.1016/J.BIOCEL.2008.01.031
P577
2008-02-12T00:00:00Z